Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Lenvatinib plus pembrolizumab shows promising activity in NSCLC

Brose M et al. SITC 2018, Abstract P392

Key clinical point: Lenvatinib/pembrolizumab shows promise in metastatic NSCLC.

Major finding: Overall response rate at 24 weeks was 33.3%.

Study details: Interim findings in 21 patients from a phase 1b/2 study.

Disclosures: Dr. Brose has received consulting fees, research grants, and honorarium from Eisai.

Read the article here.

Citation:

Brose M et al. SITC 2018, Abstract P392

This Week's Must Reads

Case studies shed light on treatment for rare form of MCL , Mori S et al. Clin Lymphoma Myeloma Leuk. 2019 Feb;19(2):e93-7.

Histopathological clues for differentiating follicular lymphomas, Servitje O et al. J Cutan Pathol. 2019;46:182-9.

Single agent daratumumab is not an option in B-cell lymphomas, Salles G et al. Clin Lymphoma Myeloma Leuk. 2019 Jan 2. doi: 10.1016/j.clml.2018.12.013.

Ibrutinib combo advances in CNS lymphoma, Grommes C et al. Blood. 2019;133(5):436-45.

Best frontline options for advanced follicular lymphoma, Shah NN et al. Clin Lymphoma Myeloma Leuk. 2019 Feb;19(2):95-102.

Must Reads in Immuno-oncology

NEO-PV-01 vaccine shows good tolerability and safety , Hu-Lieskovan S et al. SITC 2018, Abstract 07.

Lenvatinib plus pembrolizumab shows promising activity in NSCLC, Brose M et al. SITC 2018, Abstract P392

Nivolumab boosts survival over chemo for advanced melanoma, Ascierto PA et al. JAMA Oncol. 2018 Oct 25. doi: 10.1001/jamaoncol.2018.4514